Could a common ED drug ease cystic fibrosis lung inflammation?

NCT ID NCT00659529

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether sildenafil (Revatio), a drug often used for erectile dysfunction, can reduce inflammation in the lungs of people with cystic fibrosis. Thirty-six participants took increasing doses over six weeks. Researchers measured changes in sputum elastase, a marker of inflammation, and other lung health indicators.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sildenafil (Revatio)
What this could lead to
If it works, this could point toward a new way to reduce lung inflammation in cystic fibrosis, potentially improving breathing and quality of life.
What could go wrong
This is an early-phase trial with only 36 people, so results may not apply widely. Sildenafil can cause side effects like headache, flushing, and low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Jewish Health

    Denver, Colorado, 80206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.